International Clinical Trial: Safety and efficacy study in achieving ad lib consumption of peanut with Viaskin(R) peanut patch in peanut allergic infants 6 through 12 months of age

Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ISRCTN63504081) titled 'Safety and efficacy study in achieving ad lib consumption of peanut with Viaskin(R) peanut patch in peanut allergic infants 6 through 12 months of age' on June 10.

Study Type: Interventional

Study Design: Multi-center interventional open-label trial (Efficacy, Quality of life, Safety)

Primary Sponsor: DBV Technologies (France)

Condition: Treatment of patients diagnosed with peanut allergy Other

Intervention: Period #1: Open-label Treatment Period: DBV712 250 µg Regimen: 1 patch application per 24 hours Route of administration: Cutaneous Treatment duration: 36 months Assigned Intervention #1: DBV712 25...